BR112012026718A2 - antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio. - Google Patents

antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio.

Info

Publication number
BR112012026718A2
BR112012026718A2 BR112012026718A BR112012026718A BR112012026718A2 BR 112012026718 A2 BR112012026718 A2 BR 112012026718A2 BR 112012026718 A BR112012026718 A BR 112012026718A BR 112012026718 A BR112012026718 A BR 112012026718A BR 112012026718 A2 BR112012026718 A2 BR 112012026718A2
Authority
BR
Brazil
Prior art keywords
disease
disorder
treating
pharmaceutical composition
scanning
Prior art date
Application number
BR112012026718A
Other languages
English (en)
Inventor
Gertler Arieh
Elinav Eran
Halpern Zamir
Original Assignee
Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct
Yissum Res Development Company Of The Hebrew Univerity Of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct, Yissum Res Development Company Of The Hebrew Univerity Of Jerusalem filed Critical Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct
Publication of BR112012026718A2 publication Critical patent/BR112012026718A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)

Abstract

antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio. muteínas da leptina, particularmente antagonistas de leptina, com afinidade de ligação aumentada com o receptor de leptina, são providas. esses compostos, bem como a composição farmacêutica compreendendo-as, são úteis para o tratamento de qualquer distúrbio em que uma atividade indesejável ou deletéria de leptina endógena ou uma resposta imune inata alterada está implicada.
BR112012026718A 2010-04-22 2011-04-17 antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio. BR112012026718A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32690810P 2010-04-22 2010-04-22
US37947810P 2010-09-02 2010-09-02
PCT/IL2011/000322 WO2011132189A2 (en) 2010-04-22 2011-04-17 High affinity leptins and leptin antagonists

Publications (1)

Publication Number Publication Date
BR112012026718A2 true BR112012026718A2 (pt) 2017-12-19

Family

ID=44120362

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026718A BR112012026718A2 (pt) 2010-04-22 2011-04-17 antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio.

Country Status (9)

Country Link
US (1) US8969292B2 (pt)
EP (1) EP2560671B1 (pt)
JP (1) JP2013524807A (pt)
CN (1) CN102958531A (pt)
AU (1) AU2011243965A1 (pt)
BR (1) BR112012026718A2 (pt)
CA (1) CA2796706A1 (pt)
MX (1) MX2012012229A (pt)
WO (1) WO2011132189A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014024189A1 (en) * 2012-08-06 2014-02-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pegylated high affinity leptins with increased biological activity
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
CN105705641B (zh) * 2013-07-18 2021-07-13 弗拉芒区生物技术研究所 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
EP3261582B1 (en) * 2015-02-26 2021-01-06 Remodeless CV Ltd. Methods and compositions relating to leptin antagonists
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
US11123461B2 (en) 2015-02-26 2021-09-21 Remodeless Cv Ltd Treatment of ischemia and reperfusion using leptin antagonist
US10105469B2 (en) * 2015-02-26 2018-10-23 Jacob Schneiderman Composition-of-matter and method for treating cardiovascular disorders
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
CA3045700A1 (en) * 2016-12-06 2018-06-14 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
CN110548037B (zh) * 2019-09-24 2023-06-02 江西天元药业有限公司 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途
EP4138916A4 (en) 2020-04-21 2024-04-17 Remodeless Cv Ltd NEW THERAPY FOR ACUTE LUNG TISSUE INJURY
WO2024050285A2 (en) * 2022-08-31 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Leptin analogs for treating obesity and weight management

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407929B2 (en) * 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists

Also Published As

Publication number Publication date
CN102958531A (zh) 2013-03-06
US20130133089A1 (en) 2013-05-23
WO2011132189A2 (en) 2011-10-27
EP2560671B1 (en) 2014-09-24
MX2012012229A (es) 2013-03-05
JP2013524807A (ja) 2013-06-20
US8969292B2 (en) 2015-03-03
CA2796706A1 (en) 2011-10-27
WO2011132189A3 (en) 2011-12-22
AU2011243965A1 (en) 2012-12-06
EP2560671A2 (en) 2013-02-27

Similar Documents

Publication Publication Date Title
BR112012026718A2 (pt) antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio.
CY1121848T1 (el) Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης
BR112012028707A2 (pt) composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
BRPI0907735A2 (pt) anticorpo, ácido nucleico isolado, célula hospedeira, camundongo transgênico, hibridoma, composição farmacêutica, método para tratar uma condição ou uma doença associada a um distúrbio imune, cristal, proteína de fusão, e, método para preparar o anticorpo
BRPI0906997A2 (pt) Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
BR112017016705A2 (pt) agentes de ligação a tnfrsf e uso dos mesmos
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
BR112015004734A2 (pt) proteínas de fusão para tratar uma síndrome metabólica
MX2021004313A (es) Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
BR112012033225A2 (pt) análogos do glucagon
BRPI0909179A2 (pt) Composição farmacêutica, e, método de tratamento de uma doença autoimune.
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
CO6382139A2 (es) Anticuerpo anti-cmet novedoso

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 61/326,908 DE 22/04/2010 E US 61/379,478 DE 02/09/2010 REIVINDICADAS NO PCT/US2011/000322 POR NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI 2440 DE 10/10/2017 PARA APRESENTACAO DE DOCUMENTO DE CESSAO CORRETO

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]